Cargando…

CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma

BACKGROUND: Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM) is a gene family involved in multiple malignancies. CMTM4 is a member of this family and is located at chromosome 16q22.1, a locus that harbours a number of tumour suppressor genes. It has been defined...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ting, Cheng, Yingying, Wang, Pingzhang, Wang, Wenyan, Hu, Fengzhan, Mo, Xiaoning, Lv, Hongxia, Xu, Tao, Han, Wenling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609138/
https://www.ncbi.nlm.nih.gov/pubmed/26474560
http://dx.doi.org/10.1186/s13046-015-0236-4
_version_ 1782395776305987584
author Li, Ting
Cheng, Yingying
Wang, Pingzhang
Wang, Wenyan
Hu, Fengzhan
Mo, Xiaoning
Lv, Hongxia
Xu, Tao
Han, Wenling
author_facet Li, Ting
Cheng, Yingying
Wang, Pingzhang
Wang, Wenyan
Hu, Fengzhan
Mo, Xiaoning
Lv, Hongxia
Xu, Tao
Han, Wenling
author_sort Li, Ting
collection PubMed
description BACKGROUND: Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM) is a gene family involved in multiple malignancies. CMTM4 is a member of this family and is located at chromosome 16q22.1, a locus that harbours a number of tumour suppressor genes. It has been defined as a regulator of cell cycle and division in HeLa cells; however, its roles in tumourigenesis remain poorly studied. METHODS: An integrated bioinformatics analysis based on the array data from the GEO database was conducted to view the differential expression of CMTM4 across multiple cancers and their corresponding control tissues. Primary clear cell renal cell carcinoma (ccRCC) and the paired adjacent non-tumour tissues were then collected to examine the expression of CMTM4 by western blotting, immunohistochemistry, and quantitative RT-PCR. The ccRCC cell lines A498 and 786-O and the normal renal tubular epithelial cell line HK-2 were also tested for CMTM4 expression by western blotting. Cell Counting Kit-8 (CCK-8) and viable cell counting assays were used to delineate the growth curves of 786-O cells after CMTM4 overexpression or knockdown. Wound healing and transwell assays were performed to assess the cells’ ability to migrate. The effects of CMTM4 on cellular apoptosis and cell cycle progression were analysed by flow cytometry, and cell cycle hallmarks were detected by western blotting and RT-PCR. The xenograft model in nude mice was used to elucidate the function of CMTM4 in tumourigenesis ex vivo. RESULTS: By omic data analysis, we found a substantial downregulation of CMTM4 in ccRCC. Western blotting then confirmed that CMTM4 was dramatically reduced in 86.9 % (53/61) of ccRCC tissues compared with the paired adjacent non-tumour tissues, as well as in the 786-O and A498 ccRCC cell lines. Restoration of CMTM4 significantly suppressed 786-O cell growth by inducing G2/M cell cycle arrest and p21 upregulation, and cell migration was also inhibited. However, knockdown of CMTM4 led to a completely opposite effect on these cell behaviours. Overexpression of CMTM4 also markedly inhibited the tumour xenograft growth in nude mice. CONCLUSIONS: CMTM4 is downregulated and exhibits tumour-suppressor activities in ccRCC, and could be exploited as a target for ccRCC treatment.
format Online
Article
Text
id pubmed-4609138
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46091382015-10-18 CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma Li, Ting Cheng, Yingying Wang, Pingzhang Wang, Wenyan Hu, Fengzhan Mo, Xiaoning Lv, Hongxia Xu, Tao Han, Wenling J Exp Clin Cancer Res Research BACKGROUND: Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM) is a gene family involved in multiple malignancies. CMTM4 is a member of this family and is located at chromosome 16q22.1, a locus that harbours a number of tumour suppressor genes. It has been defined as a regulator of cell cycle and division in HeLa cells; however, its roles in tumourigenesis remain poorly studied. METHODS: An integrated bioinformatics analysis based on the array data from the GEO database was conducted to view the differential expression of CMTM4 across multiple cancers and their corresponding control tissues. Primary clear cell renal cell carcinoma (ccRCC) and the paired adjacent non-tumour tissues were then collected to examine the expression of CMTM4 by western blotting, immunohistochemistry, and quantitative RT-PCR. The ccRCC cell lines A498 and 786-O and the normal renal tubular epithelial cell line HK-2 were also tested for CMTM4 expression by western blotting. Cell Counting Kit-8 (CCK-8) and viable cell counting assays were used to delineate the growth curves of 786-O cells after CMTM4 overexpression or knockdown. Wound healing and transwell assays were performed to assess the cells’ ability to migrate. The effects of CMTM4 on cellular apoptosis and cell cycle progression were analysed by flow cytometry, and cell cycle hallmarks were detected by western blotting and RT-PCR. The xenograft model in nude mice was used to elucidate the function of CMTM4 in tumourigenesis ex vivo. RESULTS: By omic data analysis, we found a substantial downregulation of CMTM4 in ccRCC. Western blotting then confirmed that CMTM4 was dramatically reduced in 86.9 % (53/61) of ccRCC tissues compared with the paired adjacent non-tumour tissues, as well as in the 786-O and A498 ccRCC cell lines. Restoration of CMTM4 significantly suppressed 786-O cell growth by inducing G2/M cell cycle arrest and p21 upregulation, and cell migration was also inhibited. However, knockdown of CMTM4 led to a completely opposite effect on these cell behaviours. Overexpression of CMTM4 also markedly inhibited the tumour xenograft growth in nude mice. CONCLUSIONS: CMTM4 is downregulated and exhibits tumour-suppressor activities in ccRCC, and could be exploited as a target for ccRCC treatment. BioMed Central 2015-10-16 /pmc/articles/PMC4609138/ /pubmed/26474560 http://dx.doi.org/10.1186/s13046-015-0236-4 Text en © Li et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Li, Ting
Cheng, Yingying
Wang, Pingzhang
Wang, Wenyan
Hu, Fengzhan
Mo, Xiaoning
Lv, Hongxia
Xu, Tao
Han, Wenling
CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma
title CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma
title_full CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma
title_fullStr CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma
title_full_unstemmed CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma
title_short CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma
title_sort cmtm4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609138/
https://www.ncbi.nlm.nih.gov/pubmed/26474560
http://dx.doi.org/10.1186/s13046-015-0236-4
work_keys_str_mv AT liting cmtm4isfrequentlydownregulatedandfunctionsasatumoursuppressorinclearcellrenalcellcarcinoma
AT chengyingying cmtm4isfrequentlydownregulatedandfunctionsasatumoursuppressorinclearcellrenalcellcarcinoma
AT wangpingzhang cmtm4isfrequentlydownregulatedandfunctionsasatumoursuppressorinclearcellrenalcellcarcinoma
AT wangwenyan cmtm4isfrequentlydownregulatedandfunctionsasatumoursuppressorinclearcellrenalcellcarcinoma
AT hufengzhan cmtm4isfrequentlydownregulatedandfunctionsasatumoursuppressorinclearcellrenalcellcarcinoma
AT moxiaoning cmtm4isfrequentlydownregulatedandfunctionsasatumoursuppressorinclearcellrenalcellcarcinoma
AT lvhongxia cmtm4isfrequentlydownregulatedandfunctionsasatumoursuppressorinclearcellrenalcellcarcinoma
AT xutao cmtm4isfrequentlydownregulatedandfunctionsasatumoursuppressorinclearcellrenalcellcarcinoma
AT hanwenling cmtm4isfrequentlydownregulatedandfunctionsasatumoursuppressorinclearcellrenalcellcarcinoma